Relapsed/Refractory Multiple Myeloma Clinical Trials in New York, New York
3 recruitingNew York, New York
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Caribou Biosciences, Inc.50 enrolled16 locationsNCT05722418